Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2026
|
| Online Access: | https://doi.org/10.5281/zenodo.20382503 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866902145412890624 |
|---|---|
| author | Chu, Melinda |
| author_facet | Chu, Melinda |
| contents | <p class="MsoNormal"><strong><span>Abstract</span></strong></p> <p class="MsoNormal"><span>Microplastics and nanoplastics (MPs/NPs) are increasingly recognized as biologically active environmental particulates capable of interacting with multiple organ systems. While current research has largely focused on environmental detection and polymer degradation, emerging evidence suggests that chronic particulate exposure may contribute to inflammation, barrier dysfunction, immune dysregulation, and altered biological signaling across gastrointestinal, neurological, metabolic, and systemic pathways.</span></p> <p class="MsoNormal"><span>Cythera Bio is developing a systems-level therapeutic framework focused on reducing the biological impact of MPs/NPs through interaction-mediated mitigation, inflammatory modulation, and biologically adaptive therapeutic architectures. Rather than relying exclusively on polymer degradation, this framework emphasizes reduction of particle interaction potential through aggregation, sequestration, altered transport dynamics, barrier stabilization, and modulation of downstream inflammatory pathways.</span></p> <p class="MsoNormal"><span>The company is pursuing both wellness-oriented exposure support products and FDA-regulated therapeutic programs spanning gastrointestinal disease, neuroinflammation, aging-associated dysfunction, and systemic inflammatory biology. Companion diagnostic and monitoring frameworks may further support exposure characterization and future adaptive therapeutic strategies.</span></p> <p><strong><span><br><br></span></strong></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_20382503 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Therapeutic Strategy for Microplastics and Nanoplastics: A Systems-Level Framework for Mitigation, Inflammation, and Companion Diagnostics Chu, Melinda <p class="MsoNormal"><strong><span>Abstract</span></strong></p> <p class="MsoNormal"><span>Microplastics and nanoplastics (MPs/NPs) are increasingly recognized as biologically active environmental particulates capable of interacting with multiple organ systems. While current research has largely focused on environmental detection and polymer degradation, emerging evidence suggests that chronic particulate exposure may contribute to inflammation, barrier dysfunction, immune dysregulation, and altered biological signaling across gastrointestinal, neurological, metabolic, and systemic pathways.</span></p> <p class="MsoNormal"><span>Cythera Bio is developing a systems-level therapeutic framework focused on reducing the biological impact of MPs/NPs through interaction-mediated mitigation, inflammatory modulation, and biologically adaptive therapeutic architectures. Rather than relying exclusively on polymer degradation, this framework emphasizes reduction of particle interaction potential through aggregation, sequestration, altered transport dynamics, barrier stabilization, and modulation of downstream inflammatory pathways.</span></p> <p class="MsoNormal"><span>The company is pursuing both wellness-oriented exposure support products and FDA-regulated therapeutic programs spanning gastrointestinal disease, neuroinflammation, aging-associated dysfunction, and systemic inflammatory biology. Companion diagnostic and monitoring frameworks may further support exposure characterization and future adaptive therapeutic strategies.</span></p> <p><strong><span><br><br></span></strong></p> |
| title | Therapeutic Strategy for Microplastics and Nanoplastics: A Systems-Level Framework for Mitigation, Inflammation, and Companion Diagnostics |
| url | https://doi.org/10.5281/zenodo.20382503 |